Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242177 · ClinicalTrials.gov registry record · Phase 1
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00242177: Completed Phase 1 study, sponsored by University of Illinois at Chicago.
NCT00242177 is a Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242177, a Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
Interventions
- DRUG ACTOS (Pioglitazone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
What the finished NCT00242177 record still lists
NCT00242177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which ACTOS (Pioglitazone) is the first listed.
NCT00242177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00242177 about?
NCT00242177 is a clinical study titled "Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability". The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
What is the current status of trial NCT00242177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-10. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00242177?
The interventions under investigation include: ACTOS (Pioglitazone) (DRUG).
Who is sponsoring clinical trial NCT00242177?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00242177's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia